紫杉醇联合顺铂治疗晚期食管癌的临床观察

Clinical observation of paclitaxel plus cisplatin on treating advanced esophageal cancer

目的观察紫杉醇联合顺铂治疗晚期食管癌的疗效。方法将48例初治晚期食管癌患者随机分为两组,分别应用TP方案及PF方案行全身静脉化疗,TP组化疗方案:紫杉醇130 mg/m2d1、d8静脉滴注,顺铂20 mg/m2d1～5静脉冲入;每3周为一个化疗周期。PF组化疗方案:顺铂20 mg/m2d1～5静脉冲入,氟尿嘧啶500 mg/m2d1～5静脉滴注,每3周为一个化疗周期。所有患者均接受4～6个疗程的化疗,疗程结束后观察两组的疗效及不良反应。结果 TP方案组RR为70.8%(17/24),PF方案组RR为41.7%(10/24),TP组RR高于PF组。两组的主要不良反应均为骨髓抑制和消化道不良反应,差异均无统计学意义(P>0.05)。结论紫杉醇联合顺铂治疗晚期食管癌比顺铂联合氟尿嘧啶的近期疗效明显,且不良反应较轻微,患者均可耐受,值得临床进一步观察研究。

Objective To observe the curative effect of paclitaxel plus cisplatin in the treatment of advanced esophageal cancer. Methods Forty-eight cases of patients with advanced esophageal cancer were divided into two groups randomly, respectively used TP solutions and PF solutions of systemic vein chemotherapy. TP chemotherapy group： paclitaxel 130 mg/m2, intravenous drip,dl, d8; cisplatin 20 mg/m2, d1-5, vein into, three weeks as a cycle of chemotherapy. PF chemotherapy group： cisplatin 20 mg/m2, dl-5, vein into; fluorouracil 500 mg/m2, intravenous drip,dl-5, three weeks as a cycle of chemotherapy. All patients accepted 4-6 courses of chemotherapy,and then observed the curative effect and adverse reactions of the two groups, Results The RR of TP chemotherapy group was 70.8% （17/24）, higher than PF chemother- apy group,which was 41.7% （10/24）. The major adverse effects of the two groups were bone marrow suppression and gas- trointestinal adverse reactions,there were no statistically significant difference between the two groups （P 〉 0.05）. Con- clusion The recent curative effect of paclitaxel plus cisplatin on treating advanced esophageal cancer is obvious,and the adverse reactions is slight, patients can tolerate, it＇ s worthy of further clinical study.